Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.
about
Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health TreatmentAripiprazole: from pharmacological profile to clinical useBlonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismMouse pharmacological models of cognitive disruption relevant to schizophrenia.Animal models of schizophrenia.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study.Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine TreatmentSupportive evidence for reduced expression of GNB1L in schizophrenia.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands.Effects of gastrodia elata bl on phencyclidine-induced schizophrenia-like psychosis in mice.Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy.Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology.New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal FunctionCariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.Schizophrenia pathophysiology: are we any closer to a complete model?New drugs in psychiatry: focus on new pharmacological targets.The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.Aripiprazole in the treatment of Alzheimer's disease.Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.Glutamatergic agents for schizophrenia: current evidence and perspectives.Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation.Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteersNeurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole.The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.Modulation of 5-HT7 receptor: effect on object recognition performances in mice.Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
P2860
Q26741515-FDDB6BC2-EC54-4AF7-9B3F-FDF9A1BA2662Q26778312-E1369A9C-213E-445A-8458-C68854E20104Q27311205-FA85925A-9E06-421C-AFCD-16392799A637Q28084069-473350A4-BFBD-4C13-AAE2-12D5A2299426Q30457807-6D3BB38F-8E40-472C-8AEB-00DA417F5C31Q30462828-5E20A699-E973-48F6-9723-DF6364EEA132Q30489404-F55DEC32-6262-438C-9CAE-06450687204DQ30490077-630140E0-F474-4357-B177-8C9BDB86B722Q30524240-0ACFC707-E0F0-426D-9052-EEA09B460FDAQ33766147-710CFEC6-EF34-4158-B28F-A911F3BB3954Q33950938-9C9CBCB6-3A0E-42CD-A40F-DAC25EBA6F61Q34169978-BCB25255-F9ED-41C1-918D-D1F759ABB7B2Q34214169-4305D10F-FD8D-42A0-BA7E-B3A2D118F76CQ34513221-EFDB8792-3DBB-42F2-AF82-57D717D767ACQ34628396-F3143270-64B7-4400-93D4-A7A970554455Q34798345-F8CBDE1C-74A0-4A3F-AE1F-922C030FEA1EQ34960954-4A037D74-8598-4542-BC36-C3980BFDD67DQ35107849-F4B295A7-708D-498B-AD10-76B05ABBF100Q35659141-D29F1362-36C0-4AFD-BE45-7079A6F581BAQ35803439-A132E3ED-871A-4AC1-8D65-3F155F3F1F50Q36594948-7205BAED-62F7-43B7-AD44-E379978B3246Q36609334-04C714CD-C51F-4919-9B98-46C68217B89CQ37166063-D06C77B5-AAF1-4F9D-8AD1-81CB825F4F4CQ37484017-AA8E4BA6-94E3-4EFE-82D4-6474AADB5AEAQ37730207-444523CE-A66A-44AF-BA57-A80F07632961Q37826638-B0D6F38F-0156-4B76-895C-EFD8C694A4E8Q37954123-6676561D-4238-4115-9695-706DACBC91C9Q38062443-D8D821C5-FBDC-4AC4-ABD6-2854F55EFE84Q38076765-4CD1DFB9-3AF6-4440-94E6-957702C0C184Q38149953-B5259081-11D9-4207-91B0-A9D6C03DAD5FQ38172958-69CD37DD-7491-4303-8AF3-50E2A31AD5D8Q38248566-CEE5BB9D-AE06-4E76-B541-1F0B84A30582Q38444551-38DFF9EF-0BB1-4FD1-95EE-10392FBB3615Q38820476-4FB40687-D3BA-4E88-BB5A-8F75A4B2FB91Q39226303-B4A35021-6C44-494C-A8D1-13F52C99FFD3Q39837691-E6F90388-8248-473B-9FF1-271ECD198D7BQ41828115-42A982C8-3D69-4454-8C34-F2C6BE7CE406Q41879506-FC2F47E3-44AC-42BE-8D23-E1096F9A0661Q43540772-9579B46C-66B4-4851-83F0-7040E0FE0FF3Q46927168-0AF91E68-6E18-44C6-BE31-414C3B3B2639
P2860
Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@en
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@nl
type
label
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@en
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@nl
prefLabel
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@en
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@nl
P2093
P2860
P1433
P1476
Aripiprazole ameliorates phenc ...... nd serotonin 5-HT1A receptors.
@en
P2093
Hiroshi Furukawa
Hiroyuki Kamei
Kanae Matsui
Rina Murai
Taku Nagai
Toshitaka Nabeshima
Yukihiro Noda
P2860
P2888
P304
P356
10.1007/S00213-008-1240-6
P577
2008-08-06T00:00:00Z